Clinical trials: Controlled Hypertension
Ischaemic Central Retinal Vein Occlusion, Neovascular Glaucoma
Trial of Aganirsen in iCRVO Patients at Risk of Developing NVG
A prospective, randomised, placebo-controlled, double-masked, three-armed multi-centre phase II/III trial for the Study of a Topical Treatment of Ischaemic Central Retinal Vein Occlusion to Prevent Neovascular Glaucoma - the…
- Trial name
- STRONG (NCT02947867)
- Testing
- aganirsen
- Volunteers
- 333 people
- Sponsor
- Gene Signal SAS
Hypertension
Phase IIa Safety and Efficacy Study of SPP635 in Mild to Moderate Hypertension
This study is conducted to investigate the effect of the oral renin inhibitor SPP635 on blood pressure in patients with mild to moderate hypertension.
- Trial name
- NCT00376636
- Testing
- SPP635 (drug)
- Where
- Germany
- Volunteers
- 35 people
- Sponsor
- Speedel Pharma Ltd.
Glaucoma, Open-Angle, Ocular Hypertension
To Compare the Safety and Efficacy of Perrigo's Product to an FDA Approved Product for the Treatment of Glaucoma or Ocular Hypertension in Both Eyes
To compare the safety and efficacy of Perrigo's product to an FDA approved product in the treatment of Primary Open Angle Glaucoma or Ocular Hypertension in Both Eyes.
- Trial name
- NCT04024072
- Testing
- Brinzolamide 1% ophthalmic suspension, Azopt 1% Ophthalmic Suspension
- Where
- United States
- Volunteers
- 495 people
- Sponsor
- Padagis LLC
Hypertension
A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly
Evaluate the systolic blood pressure lowering effect of aliskiren 150mg and 300mg compared to ramipril 5mg and 10mg in elderly patients with essential systolic hypertension.
- Trial name
- NCT00368277
- Testing
- Aliskiren, Ramipril, Hydrochlorothiazide
- Where
- United States
- Volunteers
- 901 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Hypertension
Safety and Efficacy of Sitaxsentan in the Treatment of Pulmonary Arterial Hypertension
This is a clinical research study designed to evaluate an investigational new medication called sitaxsentan for the treatment of pulmonary arterial hypertension (patients with NYHA functional class II, III or IV).
- Trial name
- NCT00034307
- Testing
- sitaxsentan sodium
- Where
- 26 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- ICOS-Texas Biotechnology
Pulmonary Hypertension, Interstitial Lung Disease
A Phase 3 Trial of Inhaled Mosliciguat in PH-ILD (PHrontier)
A Phase 3, Multicenter, Randomized, Double-Blind Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Mosliciguat in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
- Conditions
- Pulmonary Hypertension, Interstitial Lung Disease, Vascular Diseases, Cardiovascular Diseases
- Trial name
- NCT07816185
- Testing
- Mosliciguat, Dry Powder Inhaler
- Where
- 3 sites in United States
- Volunteers
- 376 people
- Sponsor
- Pulmovant, Inc.
Pulmonary Arterial Hypertension
Clinical Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
Clinical study to assess the efficacy, safety, and tolerability of macitentan in subjects with Eisenmenger Syndrome.
- Trial name
- MAESTRO (NCT01743001)
- Testing
- Macitentan 10 mg
- Where
- 55 sites in United States, Austria and 19 more
- Volunteers
- 226 people
- Sponsor
- Actelion
Pulmonary Arterial Hypertension
A Study to Investigate Safe and Tolerable Dose of GMA301 Injection in Healthy Volunteers
This study is a single-centre, randomized, double-blind, placebo-controlled, dose escalation study to assess the safety, tolerability and PK of GMA301 Injection in healthy subjects.
- Trial name
- NCT04505137
- Testing
- GMA301 Injection
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Gmax Biopharm Australia Pty Ltd.
Hypertension
Clinical Study to Evaluate the Antihypertensive Efficacy and Safety of Fimasartan in Hypertension Patients
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan (BR-A-657•K) 60 mg~120 mg in patients with mild to moderate essential hypertension.
- Trial name
- NCT00922480
- Testing
- Fimasartan, Losartan (Control)
- Volunteers
- 506 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Hypertension, Hypercortisolemia
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically…
- Conditions
- Hypertension, Hypercortisolemia, Cushing Syndrome
- Trial name
- LINC CARE (NCT07247162)
- Testing
- Osilodrostat
- Where
- 3 sites in United States
- Volunteers
- 63 people
- Sponsor
- RECORDATI GROUP
Hypertension, Pulmonary
A Study to Assess the Efficacy and Safety of 20, 40, and 80mg of Sildenafil Three Times a Day in the Treatment of Pulmonary Arterial Hypertension
To evaluate the effect of three doses of oral sildenafil (20, 40 and 80 mg three times a day [TID]) on exercise capacity, as measured by the 6-Minute Walk test, as well as the safety and tolerability, after 12 weeks of treatment…
- Trial name
- NCT00644605
- Testing
- sildenafil
- Where
- 68 sites in United States, Australia and 21 more
- Volunteers
- 275 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Hypertension
Nebivolol in Patients With Systolic Stage 2 Hypertension
The primary object of this study is to evaluate the efficacy and safety of 6 weeks of nebivolol monotherapy compared with placebo in patients with systolic stage 2 hypertension.
- Trial name
- NEB-MD-20 (NCT01057251)
- Testing
- Nebivolol
- Where
- 36 sites in United States
- Volunteers
- 433 people
- Sponsor
- Forest Laboratories
Idiopathic Pulmonary Fibrosis
Efficacy, Safety, and Tolerability Study of Pirfenidone in Combination With Sildenafil in Participants With Advanced Idiopathic Pulmonary Fibrosis (IPF) and Intermediate or High Probability of Group 3 Pulmonary Hypertension
This Phase IIb, randomized, placebo-controlled, multicenter, international study will evaluate the efficacy, safety, and tolerability of sildenafil or placebo added to pirfenidone (Esbriet) treatment in participants with advanced…
- Trial name
- NCT02951429
- Testing
- Pirfenidone, Sildenafil
- Where
- 56 sites in Belgium, Canada and 11 more
- Volunteers
- 177 people
- Sponsor
- Hoffmann-La Roche
Open Angle Glaucoma, Ocular Hypertension
Equivalence Study of Dorzolamide 2% Eye Drops Solution
The study aims to prospectively prove the equivalence of the test product and the reference solution in lowering intraocular pressure in patients with open angle glaucoma and ocular hypertension.
- Trial name
- NCT00878917
- Testing
- Dorzolamide 2 % eye drops solution
- Where
- Germany
- Volunteers
- 32 people
- Sponsor
- Alfred E. Tiefenbacher (GmbH & Co. KG)
Hypertension
A Study in Chinese Mild to Moderate Hypertensive Patients Comparing the Efficacy of Co-Diovan With Diovan.
Valsartan, an orally active angiotensin II receptor blocker, is registered in most countries worldwide for the treatment of hypertension. In China the usual recommended starting and maintenance dose is 80 mg o.d.
- Trial name
- NCT00250562
- Testing
- valsartan plus hydrochlorothiazide
- Where
- United States
- Volunteers
- 1,171 people, healthy volunteers welcome
- Sponsor
- Novartis
Essential Hypertension
A Clinical Study to Evaluate Efficacy and Safety of Fimasartan/Hydrochlorothiazide Combination-therapy
The purpose of this study is to evaluate the antihypertensive efficacy and safety of Fimasartan/Hydrochlorothiazide combination 60/12.5mg~120/12.5mg in patients with essential hypertension who are not controlled by fimasartan…
- Trial name
- NCT01258673
- Testing
- Fimasartan/HCTZ combination, Fimasartan
- Where
- South Korea
- Volunteers
- 263 people
- Sponsor
- Boryung Pharmaceutical Co., Ltd
Glaucoma
Study of AR-12286 Versus Latanoprost in Patients With Elevated Intraocular Pressure
A 28 day study of the safety and efficacy of two concentrations of topical AR-12286 in treating ocular hypertension and open-angle glaucoma compared to latanoprost.
- Trial name
- NCT01060579
- Testing
- AR-12286 0.5% ophthalmic solution, AR-12286 0.25% Ophthalmic solution, Latanoprost ophthalmic solution
- Where
- 18 sites in United States
- Volunteers
- 217 people
- Sponsor
- Aerie Pharmaceuticals
Heart Failure
Efficacy of Candesartan on Symptomatic Heart Failure in Treating Diabetic and Hypertensive Patients.
The purpose of this study is to determine the effects of candesartan, once daily (QD), on the N-terminal pro-B-type Natriuretic Peptide laboratory marker in subjects with symptomatic heart failure with diastolic dysfunction.
- Trial name
- NCT00775840
- Testing
- Candesartan
- Where
- 37 sites in Germany
- Volunteers
- 22 people
- Sponsor
- Takeda
Primary Open-angle Glaucoma, Ocular Hypertension
A Multi-center, Randomized, Blinded Evaluator, Active Control, Parallel, Phase III Study to Evaluate the Efficacy and Safety of TJO-002 in POAG or Ocular Hypertension Patients
TJO-002 or Acitve Control was administered on primary open-angle glaucoma or ocular hypertension patients for 12 weeks. This clinical trial study has hypothesize TJO-002 administration groups are not inferior to Active control…
- Trial name
- NCT03419975
- Testing
- TJO-002, Latanoprost
- Where
- South Korea
- Volunteers
- 146 people
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
Glaucoma, Ocular Hypertension
AR-12286 in Combination With Latanoprost
This is a double-masked, randomized, multi-center, active-controlled, crossover comparison of the addition of AR-12286 or timolol to latanoprost in the treatment of elevated intraocular pressure (IOP).
- Trial name
- NCT01302249
- Testing
- Latanoprost 0.005%, AR-12286 Ophthalmic Solution 0.5%, Timolol maleate ophthalmic solution 0.5%
- Where
- 15 sites in United States
- Volunteers
- 66 people
- Sponsor
- Aerie Pharmaceuticals